REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Regenxbio's operating cash flow for the twelve months ending Jun 30, 2026 was -$246.67M. For fiscal 2025 it was -$123.96M. The highest annual figure on record is $218.88M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$123.96M | – |
| FY2024 | Dec 31, 2024 | -$173.13M | – |
| FY2023 | Dec 31, 2023 | -$218.41M | – |
| FY2022 | Dec 31, 2022 | -$207.49M | -194.8% |
| FY2021 | Dec 31, 2021 | $218.88M | – |
| FY2020 | Dec 31, 2020 | -$54.06M | – |
| FY2019 | Dec 31, 2019 | -$107.71M | -202.9% |
| FY2018 | Dec 31, 2018 | $104.65M | – |
| FY2017 | Dec 31, 2017 | -$57.99M | – |
| FY2016 | Dec 31, 2016 | -$48.56M | – |
| FY2015 | Dec 31, 2015 | -$22.52M | – |
| FY2014 | Dec 31, 2014 | -$2.40M | – |
| FY2013 | Dec 31, 2013 | -$3.01M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$62.24M | – |
| Q1 FY2026 | Mar 31, 2026 | -$76.19M | -326.5% |
| Q4 FY2025 | Dec 31, 2025 | -$52.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$55.96M | – |
| Q2 FY2025 | Jun 30, 2025 | -$49.34M | – |
| Q1 FY2025 | Mar 31, 2025 | $33.63M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.62M | – |
| Q3 FY2024 | Sep 30, 2024 | -$40.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$55.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$40.76M | – |
| Q3 FY2023 | Sep 30, 2023 | -$49.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$47.32M | – |
| Q1 FY2023 | Mar 31, 2023 | -$80.92M | – |
| Q4 FY2022 | Dec 31, 2022 | -$39.37M | -111.5% |
| Q3 FY2022 | Sep 30, 2022 | -$50.46M | – |
| Q2 FY2022 | Jun 30, 2022 | -$61.75M | – |
| Q1 FY2022 | Mar 31, 2022 | -$55.91M | – |
| Q4 FY2021 | Dec 31, 2021 | $341.50M | +765.3% |
| Q3 FY2021 | Sep 30, 2021 | -$42.50M | – |
| Q2 FY2021 | Jun 30, 2021 | -$36.07M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.05M | – |
| Q4 FY2020 | Dec 31, 2020 | $39.47M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.46M | – |
| Q2 FY2020 | Jun 30, 2020 | -$21.50M | – |
| Q1 FY2020 | Mar 31, 2020 | -$35.57M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.51M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.15M | – |
| Q2 FY2019 | Jun 30, 2019 | -$23.75M | -133.8% |
| Q1 FY2019 | Mar 31, 2019 | -$29.30M | -150.4% |
| Q4 FY2018 | Dec 31, 2018 | -$4.14M | – |
| Q3 FY2018 | Sep 30, 2018 | -$19.56M | – |
| Q2 FY2018 | Jun 30, 2018 | $70.21M | – |
| Q1 FY2018 | Mar 31, 2018 | $58.13M | – |
| Q4 FY2017 | Dec 31, 2017 | -$13.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$17.14M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.55M | – |
| Q1 FY2017 | Mar 31, 2017 | -$17.48M | – |
| Q4 FY2016 | Dec 31, 2016 | -$20.42M | – |
| Q3 FY2016 | Sep 30, 2016 | -$11.82M | – |
See a number that looks wrong?